How concerned should we be over the long-term safety of growth hormone therapy?

被引：0
|
作者：
Tritos, Nicholas A. [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2017年 / 5卷 / 02期
关键词：
CHILDHOOD; MORTALITY; ADULTS; SAGHE;
D O I：
10.1016/S2213-8587(16)30423-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：79 / 81
页数：4
相关论文
共 50 条
  • [21] Long-term growth hormone replacement therapy in hypopituitary adults
    Verhelst, J
    Abs, R
    [J]. DRUGS, 2002, 62 (16) : 2399 - 2412
  • [22] LONG-TERM EFFECT OF GROWTH HORMONE THERAPY IN DECOMPENSATED CIRRHOSIS
    Kumari, Sunita
    Leishangthem, Bidyalaxmi
    Singh, Akash
    De, Arka
    Kalra, Naveen
    Singh, Virendra
    [J]. HEPATOLOGY, 2019, 70 : 35A - 36A
  • [23] Long-term results of growth hormone therapy in Turner syndrome
    Bramswig, JH
    [J]. ENDOCRINE, 2001, 15 (01) : 5 - 13
  • [24] LONG-TERM EFFECT OF GROWTH HORMONE THERAPY IN DECOMPENSATED CIRRHOSIS
    Kumari, Sunita
    De, Arka
    Roy, Akash
    Kalra, Naveen
    Singh, Virendra
    [J]. HEPATOLOGY, 2020, 72 : 90A - 90A
  • [25] Growth hormone status during long-term hexarelin therapy
    Rahim, A
    O'Neill, PA
    Shalet, SM
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (05): : 1644 - 1649
  • [26] Long-term results of growth hormone therapy in turner syndrome
    J. H. Bramswig
    [J]. Endocrine, 2001, 15 : 5 - 13
  • [27] Long-Term Safety of Growth Hormone Replacement after CNS Irradiation
    Mackenzie, S.
    Craven, T.
    Gattamaneni, H. R.
    Swindell, R.
    Shalet, S. M.
    Brabant, G.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (09): : 2756 - 2761
  • [28] Long-term safety of recombinant human growth hormone in Turner syndrome
    Bolar, Katrina
    Hoffman, Andrew R.
    Maneatis, Thomas
    Lippe, Barbara
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (02): : 344 - 351
  • [29] How Long Should We Maintain Long-Term Azithromycin Treatment in Cystic Fibrosis Patients?
    Willekens, Julie
    Eyns, Hanneke
    Malfroot, Anne
    [J]. PEDIATRIC PULMONOLOGY, 2015, 50 (01) : 103 - 104
  • [30] HOW AND WHEN SHOULD LONG-TERM SAFETY DATA BE OBTAINED FOR HYPOLIPIDEMIC AGENTS
    PIERCE, LR
    [J]. RISK/BENEFIT ANALYSIS FOR THE USE AND APPROVAL OF THROMBOLYTIC, ANTIARRHYTHMIC, AND HYPOLIPIDEMIC AGENTS, 1989, : 241 - 248
12345